Wednesday, November 21, 2018
Close  
  • share this

Lacson questions report recommending filing of Dengvaxia charges vs Aquino

By: - Reporter / @MAgerINQ
/ 05:58 PM May 16, 2018

A committee report recommending the filing of charges against former President Benigno Aquino III and his officials over the Dengvaxia controversy hit a bump when it was read on the Senate floor on Wednesday.

Committee Report No. 368 was filed for plenary discussion on April 30 by the Senate Blue Ribbon Committee chaired by Senator Richard Gordon, jointly with the committees on health and demography and finance.

ADVERTISEMENT

READ: Senate panel files proposals to avoid Dengvaxia mistakes

But Senator Panfilo Lacson, who did not sign the report, took the floor and raised a couple of questions regarding the number of signatures obtained for the report.

FEATURED STORIES

“On its face, out of the 22 members of the three committees, 14 signed the report,” Lacson said. “However, upon the perusal of the report, particularly its signature page and its various attachments, this representation noticed that some members of the three committees signed the report with concurring and dissenting votes.”

“In addition, Mr. President, some senators signed with reservations, while Senators Drilon and de Lima, joined by their colleagues in the minority, filed their separate dissenting opinions. Others, or at least this representation, did not sign,” he continued, referring to Minority Leader Franklin Drilon and detained Senator Leila de Lima, also an opposition member.

Lacson asked whether those who signed with concurring and dissenting opinions and those with reservations should be counted in determining the majority.

“The second issue, Mr. President, is in cases where several committees are conducting inquiry in aid of legislation involving certain issues, assuming that the primary committee prepares the report: Is the majority requirement for purposes of filing and consideration by the Senate on a per committee-basis or all the members of the different committees lumped together?” he asked again.

He added that the Blue Ribbon Committee has 20 members while the health and finance panels have 14 and 20 members, respectively.

Lacson noted that under Section 22 of the Rules of Procedures Governing Inquiries in Aid of Legislation, the report should be approved by a majority vote of all its members.

“Concurring and dissenting reports may likewise be made by the members who do not sign the majority report within 72 hours from the approval of the report. The number of members who sign reports concurring in the conclusions of the Committee Report shall be taken into account in determining whether the report has been approved by a majority of the members,” he said, quoting the said provision.

ADVERTISEMENT

“Provided, and I’d like to highlight, that the vote of a member who submits both a concurring and dissenting opinion shall not be considered as part of the majority unless he expressly indicates his vote for the majority decision,” he added.

In view of the said provision, Lacson then asked the chamber “whether the required majority was obtained for us to consider Committee Report No. 368.”

Instead of seeking an immediate answer from the chamber, Lacson moved that the report be referred to the Senate Committee on Rules for discussion and resolution.

No senator present on the floor objected to Lacson’s motion. /ee

READ: Lacson won’t sign Dengvaxia report due to Gordon’s ‘unreasonable’ remark

Read Next
Don't miss out on the latest news and information.
View comments

Subscribe to INQUIRER PLUS to get access to The Philippine Daily Inquirer & other 70+ titles, share up to 5 gadgets, listen to the news, download as early as 4am & share articles on social media. Call 896 6000.

TAGS: Anti-Dengue Vaccine, Benigno Aquino III, Dengvaxia, Senate blue ribbon committee
For feedback, complaints, or inquiries, contact us.


© Copyright 1997-2018 INQUIRER.net | All Rights Reserved

We use cookies to ensure you get the best experience on our website. By continuing, you are agreeing to our use of cookies. To find out more, please click this link.